Innovative Testing Solutions
Neodocs has developed user-friendly test kits that allow individuals to conduct health assessments using their smartphones. Users simply apply a sample to a test card, which reacts with embedded chemical reagents to produce a visual change. By capturing an image of the test card with the Neodocs app, users receive immediate, accurate results on their devices.
The company’s product lineup includes the Kidney Care Kit and the UTI Care Kit. The Kidney Care Kit measures the urine albumin-creatinine ratio along with 14 other parameters, facilitating early detection of chronic kidney disease. The UTI Care Kit screens for urinary tract infections by analyzing 10 different parameters, providing quick and reliable results. To date, Neodocs has sold over 200,000 test cards, with more than 4,000 doctors across India incorporating these tools into their practices.
Strategic Partnerships and Collaborations
To broaden its impact, Neodocs collaborates with leading pharmaceutical companies such as Cipla, Eris, Sun Pharma, AstraZeneca, Bayer, and RPG Life Sciences. These partnerships aim to enhance the availability and integration of Neodocs’ testing solutions within the healthcare ecosystem. Additionally, the company works with government bodies in Maharashtra and Rajasthan to digitize testing services in remote areas, improving healthcare accessibility in underserved regions.
Funding and Future Plans
In February 2024, Neodocs secured $2 million in seed funding led by Omidyar Network India, with participation from Y Combinator, 9Unicorns, Gemba Capital, Titan Capital, and prominent angel investors. This infusion of capital is earmarked for expanding Neodocs’ presence into international markets, including Europe, Australia, the Middle East, and the Americas. The company is also developing instant finger-prick blood tests, which will allow users to obtain results on their smartphones by simply capturing a picture, further simplifying the diagnostic process.
Vision for the Future
Neodocs envisions a future where proactive and preventive healthcare is the norm. By providing affordable, real-time diagnostic tools, the company seeks to transform healthcare from a reactive system to one focused on early detection and continuous monitoring. With plans to conduct 100 million tests over the next three years, Neodocs is poised to make a significant impact on global health outcomes.
Through its innovative approach and commitment to accessibility, Neodocs is redefining the landscape of personal health diagnostics, empowering individuals to take control of their health with the convenience of smartphone technology.
